MTP - Midatech surges on the promise of drug delivery system

JuSun/iStock via Getty Images Midatech Pharma (MTP) has added ~59.8% in the pre-market on above average volume after the company shared in vitro data indicating the potential of its Q-Sphera platform. Q-Sphera is “a disruptive micro-technology” according to the company. It is designed to prolong the and control the release of therapeutics over an extended period of time (from weeks to months). The company expects the results will open significant opportunities for its Q-Sphera technology noting that “reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors,” Midatech also updated on its clinical development programs. Monoclonal antibody therapeutics MTX214 and MTX216 are expected to undergo dosing for in vivo studies in the next few weeks. MTD211, a long-acting formulation of brexpiprazole developed by the company is indicated for the treatment of schizophrenia and adjunctive treatment of major depressive disorder ((MDD)). Marketed under the brand name Rexulti, brexpiprazole

For further details see:

Midatech surges on the promise of drug delivery system